炎症性肠病患者生物制剂使用趋势及其治疗结局——丹麦全国队列研究
该丹麦全国队列研究纳入2011至2018年间首次接受生物制剂治疗的6036例炎症性肠病患者(51%为溃疡性结肠炎,49%为克罗恩病),分析生物制剂使用趋势、治疗持续性、手术率及医疗费用。结果显示溃疡性结肠炎和克罗恩病患者生物制剂累积使用率均上升,英夫利西单抗仍是最常用的一线生物制剂,治疗持续性偏低,约三分之一患者更换为第二种生物制剂,手术率和门诊及手术费用下降。
要点
- 2011至2018年间,溃疡性结肠炎患者生物制剂累积使用率从5.0%升至10.8%,克罗恩病患者从8.9%升至14.5%。
- 溃疡性结肠炎患者1年和3年治疗持续性分别为44.3%和16.9%,克罗恩病患者分别为59.9%和33.6%。
- 32.8%的患者更换为第二种生物制剂;溃疡性结肠炎和克罗恩病患者手术率均下降。
核心结论
- 炎症性肠病患者一线生物制剂治疗持续性低,约三分之一患者更换治疗;手术率和直接费用随时间下降,但是否与生物制剂使用相关尚待确定。
研究设计与样本
- 丹麦全国队列研究,基于丹麦国家患者登记处识别2011至2018年间首次接受生物制剂治疗的炎症性肠病患者,共6036例(51%为溃疡性结肠炎,49%为克罗恩病),分析生物制剂使用、手术和医疗费用的时间趋势。
主要发现
- 2011至2018年间,溃疡性结肠炎患者生物制剂累积使用率从5.0%升至10.8%,克罗恩病患者从8.9%升至14.5%。
- 英夫利西单抗仍是溃疡性结肠炎和克罗恩病患者最常处方的一线生物制剂。
- 溃疡性结肠炎患者1年和3年治疗持续性分别为44.3%和16.9%,克罗恩病患者分别为59.9%和33.6%。
- 总体32.8%的患者更换为第二种生物制剂。
- 溃疡性结肠炎(P = 0.015)和克罗恩病(P = 0.008)患者手术率均下降,溃疡性结肠炎在Cox回归模型中仍显著(P = 0.002);两组门诊和手术费用也下降。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapeutic management of inflammatory bowel diseases (IBD) is rapidly evolving, with an expanding armoury of biological drugs at our disposal. However, real-world findings about treatment persistence and the impact of biologicals on surgery remain inconsistent. AIMS: This study aimed to investigate trends in biological use and surgery rates in a nationwide cohort of biological-naïve IBD patients. METHODS: Patients with IBD who initiated biological treatment between 2011 and 2018 were identified in the Danish National Patient Registry. Data on use of biologicals, surgeries and healthcare costs were retrieved and analysed for time trends. RESULTS: Between 2011 and 2018, a total of 6,036 IBD (51% ulcerative colitis (UC), 49% Crohn's disease (CD)) patients received biological treatment for the first time. Cumulative use of biologicals increased from 5.0% to 10.8% among UC and 8.9%-14.5% among CD patients. Infliximab remained the most-prescribed first-line biological for UC and CD. Treatment persistence was 44.3% and 16.9% after 1 and 3 years in UC, compared to 59.9% and 33.6% in CD patients. Overall, 32.8% of patients switched to a second biological. Surgery rates decreased in both UC (P = 0.015) and CD (P = 0.008) patients and remained significant for UC in the Cox regression model (P = 0.002). Outpatient and surgical costs also fell among both UC and CD patients. CONCLUSIONS: Persistence rates for first-line biologicals among IBD patients were low and one-third switched treatment. Surgery rates and direct costs decreased over time, but whether this is related to the use of biologicals has yet to be determined.
引用
- Zhao M, Sall Jensen M, Knudsen T, et al. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study. Aliment Pharmacol Ther. 2021. PMID: 34881439. doi:10.1111/apt.16723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。